{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:49:35Z","timestamp":1793047775199,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"\n Importance<\/jats:title>\n Psilocybin shows promise in treating depression, although limitations of previous research warrant further research.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the efficacy and safety of oral psilocybin, 25 mg, with adjunct psychotherapy in treatment-resistant depression (TRD).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a 2-center, triple-blinded (investigator, participant, rater), phase 2b, active placebo-controlled randomized clinical trial. Participants were randomized to 4 groups in ratios 2:2:1:1, receiving 2 doses 6 weeks apart (week 0, week 6) as follows: (1) placebo (nicotinamide, 100 mg) then psilocybin, 25 mg; (2) psilocybin, 5 mg, then 25 mg; and (3) psilocybin, 25 mg, then 5 mg or psilocybin, 25 mg, twice embedded in psychotherapeutic sessions. Participants aged 25 to 65 years with TRD and withdrawn from antidepressant medication were recruited predominantly from 2 outpatient settings in Germany. Study data were analyzed from April 2024 to November 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Oral synthetic psilocybin, 25 mg; psilocybin, 5 mg; or nicotinamide, 100 mg administered with psychotherapeutic sessions.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was treatment response (\u226550% reduction on the Hamilton Rating Scale for Depression [HAMD17]) at week 6 before the second dose. Key secondary end points were response on the Beck Depression Inventory II (BDI-II) and mean change from baseline on the HAMD17 and BDI-II at week 6.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 144 participants (mean [SD] age, 42.6 [10.8] years; 85 male [59.0%]) were randomized, and 142 were included in the primary efficacy analysis: psilocybin, 25 mg (n\u2009=\u200947), psilocybin, 5 mg (n\u2009=\u200948), and nicotinamide (n\u2009=\u200947). Response rates on the primary end point were 17.0% in the group receiving psilocybin, 25 mg; 12.5% in the group receiving psilocybin, 5 mg; and 10.6% in the group receiving nicotinamide. The first hierarchical comparison was nonsignificant (psilocybin, 25 mg vs nicotinamide, adjusted odds ratio [OR], 1.73; 95% CI, 0.53-6.23;\n P<\/jats:italic>\n \u2009=\u2009.19; 1-sided \u03b1\n P<\/jats:italic>\n \u2009=\u2009.03); consequently, further formal testing was not performed. Analyses of key secondary end points (mean changes from baseline on HAMD17 and BDI-II) provided exploratory evidence of a clinically meaningful effect of psilocybin, 25 mg. Psilocybin, 25 mg, was linked to adverse events, predominantly acutely, and was associated with higher reports of suicidal ideation on dosing days (4% vs 1%-2% in comparator conditions). Two serious adverse reactions were reported after psilocybin, 25 mg, including 1 case of hallucinogen persisting perception disorder.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n In this randomized clinical trial, psilocybin, 25 mg, with adjunct psychotherapy, was associated with a clinically meaningful reduction in depressive symptoms in individuals with TRD, although findings did not show a significant effect on the primary outcome. The treatment was well tolerated by most participants, although safety signals were observed. While overall this constituted an inconclusive trial, these results add to the existing evidence on the potential of psilocybin treatment for depression.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04670081<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.0132","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:30:36Z","timestamp":1773847836000},"page":"448","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression"],"prefix":"10.1001","volume":"83","author":[{"given":"Lea J.","family":"Mertens","sequence":"first","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koslowski","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"},{"name":"German Center for Mental Health, partner site Berlin-Potsdam, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Betzler","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"},{"name":"German Center for Mental Health, partner site Berlin-Potsdam, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Brand","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Evens","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"},{"name":"Department of Psychology, Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"K\u00e4rtner","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jungaberle","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"},{"name":"MIND Foundation, Berlin, Germany"},{"name":"OVID Health Systems GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Jungaberle","sequence":"additional","affiliation":[{"name":"MIND Foundation, Berlin, Germany"},{"name":"OVID Health Systems GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Maji\u0107","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"},{"name":"German Center for Mental Health, partner site Berlin-Potsdam, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian N.","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Str\u00f6hle","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Scharf","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Spangemacher","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"},{"name":"MIND Foundation, Berlin, Germany"},{"name":"OVID Health Systems GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Assadi","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scharif","family":"Bahri","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilith","family":"Becher","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca V.","family":"F\u00e4rber","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Kirchen","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Kulakova","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"},{"name":"German Center for Mental Health, partner site Berlin-Potsdam, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Kunz","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Meijer","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charit\u00e9 Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rohrmoser","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wellek","sequence":"additional","affiliation":[{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Core Facility of Biostatistics, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz M.","family":"Berger","sequence":"additional","affiliation":[{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"Core Facility of Biostatistics, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"},{"name":"German Center for Mental Health, partner site Mannheim-Heidelberg-Ulm, Mannheim, Germany"},{"name":"OVID Health Systems GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10440","key":"yoi260007r2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","author":"Ferrari","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"yoi260007r5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2022.3860","article-title":"Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study.","volume":"80","author":"Lundberg","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi260007r6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12888-019-2222-4","article-title":"The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study.","volume":"19","author":"Jaffe","year":"2019","journal-title":"BMC Psychiatry"},{"issue":"7","key":"yoi260007r7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"yoi260007r8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin.","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"issue":"5","key":"yoi260007r9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial.","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"yoi260007r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomized clinical trial.","volume":"56","author":"von Rotz","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"9","key":"yoi260007r11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"yoi260007r12","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"yoi260007r13","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin vs escitalopram for depression.","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"yoi260007r14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078084","article-title":"Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.","volume":"385","author":"Metaxa","year":"2024","journal-title":"BMJ"},{"key":"yoi260007r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2022.100104","article-title":"Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)\u2014rationale and study design.","volume":"1","author":"Mertens","year":"2022","journal-title":"Neurosci Appl"},{"issue":"9","key":"yoi260007r16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1056\/NEJMc2108082","article-title":"Psilocybin for depression.","volume":"385","author":"Gr\u00fcnder","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"yoi260007r17","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"yoi260007r18","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse events in studies of classic psychedelics: a systematic review and meta-analysis.","volume":"81","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi260007r19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"yoi260007r20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/09540261.2018.1486289","article-title":"Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.","volume":"30","author":"Garcia-Romeu","year":"2018","journal-title":"Int Rev Psychiatry"},{"issue":"6","key":"yoi260007r21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety.","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"12","key":"yoi260007r22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"4","key":"yoi260007r23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"yoi260007r25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0272-7358(88)90050-5","article-title":"Psychometric properties of the Beck depression inventory: twenty-five years of evaluation.","volume":"8","author":"Beck","year":"1988","journal-title":"Clin Psychol Rev"},{"issue":"2","key":"yoi260007r26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/bmjebm-2020-111600","article-title":"Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression.","volume":"27","author":"Hengartner","year":"2022","journal-title":"BMJ Evid Based Med"},{"key":"yoi260007r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"12","key":"yoi260007r28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from 3 multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi260007r31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2215-0366(23)00363-2","article-title":"Treatment with psychedelics is psychotherapy: beyond reductionism.","volume":"11","author":"Gr\u00fcnder","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"yoi260007r32","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231172254","article-title":"The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.","volume":"13","author":"Evens","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"issue":"26","key":"yoi260007r33","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3238\/arztebl.m2024.0224","article-title":"Psilocybin as a disease-modifying drug\u2014a salutogenic approach in psychiatry.","volume":"121","author":"Spangemacher","year":"2024","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"yoi260007r34","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1521\/pedi_2013_27_070","article-title":"Influence of personality on the outcome of treatment in depression: systematic review and meta-analysis.","volume":"28","author":"Newton-Howes","year":"2014","journal-title":"J Pers Disord"},{"issue":"9","key":"yoi260007r35","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S2215-0366(20)30099-7","article-title":"Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications.","volume":"7","author":"Schramm","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"yoi260007r36","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"10","key":"yoi260007r37","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial.","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"yoi260007r38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1742-1241.2005.00440.x","article-title":"Efficacy of escitalopram in patients with severe depression: a pooled analysis.","volume":"59","author":"Llorca","year":"2005","journal-title":"Int J Clin Pract"},{"issue":"9","key":"yoi260007r39","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials.","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1572","key":"yoi260007r40","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1098\/rstb.2010.0394","article-title":"Lessons learned from placebo groups in antidepressant trials.","volume":"366","author":"Mora","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"7","key":"yoi260007r41","doi-asserted-by":"publisher","first-page":"e2524119","DOI":"10.1001\/jamanetworkopen.2025.24119","article-title":"Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: a meta-analysis.","volume":"8","author":"Hieronymus","year":"2025","journal-title":"JAMA Netw Open"},{"key":"yoi260007r24","volume-title":"German Version of the GRID Hamilton Rating Scale for Depression (GRID-HAMD)","author":"Schmitt"},{"key":"yoi260007r1","unstructured":"Vizhub Health Data. Evaluation IfHM\u2014Global Health Data Exchange (GHDx). Accessed October 12, 2024."},{"key":"yoi260007r3","unstructured":"European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products in the treatment of depression\u2014revision 2. Accessed December 18, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-2_en.pdf"},{"key":"yoi260007r4","unstructured":"US Food and Drug Administration (FDA). Major depressive disorder: developing drugs for treatment\u2014guidance for industry (revision 1). Accessed December 18, 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/major-depressive-disorder-developing-drugs-treatment"},{"key":"yoi260007r29","unstructured":"SAS Institute. SAS\/STAT 9.4 support, version 9.4. Accessed April 15, 2024. https:\/\/support.sas.com\/en\/software\/sas-stat-support.html"},{"key":"yoi260007r30","unstructured":"R Project. The R project for statistical computing, version 4.4. Accessed April 15, 2024. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2846478\/jamapsychiatry_mertens_2026_oi_260007_1777052914.3703.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:00:39Z","timestamp":1778079639000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2846478"}},"subtitle":["The EPISODE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0132","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}